Valuation
- Market cap
- 12,567,000
- Revenue TTM
- $0
- Net income TTM
- $-6,940,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 75,100
- Avg volume
- 91,442
- Day's range
- $5.12 – $5.63
- Shares out
- 2,293,000
- Stochastic %K
- 2%
- Beta
- 1.67
- Analysts
- Strong Buy
- Price target
- —
Company profile
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiar...
Show more
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 416-477-1708
- Website
- https://psyencebiomed.com
- Address
- 121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada
Latest news
No headlines yet.
